There has been a recommendation in Brazil for the non-use of GLP1 analogues to treat obesity for over 10 years. This determination occurred because of adverse effects such as pancreatitis and pancreatic neoplasia. The alerts came from Europe and the United States.
1. WORLD HEALTH ORGANIZATION. Diabetes – Fact Sheet, 2013. Disponível em: 2. WORLD HEALTH ORGANIZATION. Noncommunicable diseasescountry profile – Brazil. 2010. Disponível em: 3. SOCIEDADE BRASILEIRA DE DIABETES. Diretrizes da Sociedade Brasileira de Diabetes, 2009. Disponível em: 4. EUROPEAN MEDICINES AGENCY. European Medicines Agency 2011 Priorities for Drug Safety Research - Anti diabetic drugs: Cardio/cerebrovascular adverse effect and pancreatitis/ pancreatic cancer. Julho/2010. Disponível em: 5. BUTLER, A. E. et al. Marked Expansion of Exocrine and Endocrine Pancreas with Incretin Therapy in Humans with increased Exocrine Pancreas Dysplasia and the potential for Glucagon-producing Neuroendocrine Tumors. 22 Março 2013. Disponível em: 6. U.S. FOOD AND DRUG ADMINISTRATION. Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication - Reports of Possible Increased Risk of Pancreatitis and Precancerous Findings of the Pancreas. Março/2013. Disponível em: 7. EUROPEAN MEDICINES AGENCY. Assessment report for GLP-1 based therapies. 25 Julho 2013. Disponível em: 8. AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Anvisa esclarece questões sobre indicação e segurança do medicamento Victoza (Liraglutida) - Informe SNVS/Anvisa/Nuvig/GFARM nº 07, de 06 de setembro de 2011. Disponível em:
Some but not all GLP1 receptor agonists are approved for obesity in people with or without diabetes as liraglutide and semaglutide but in higher doses and different commercial names than the preparation used in diabetes
Few GLP1 agonists are approved for obesity in people with or without diabetes like liraglutide and semaglutide
- Badges
- Science method